INT105330

Context Info Confidence 0.63 First Reported 2002 Last Reported 2010 Negated 0 Speculated 3 Reported most in Body Documents 31 Total Number 34 Disease Relevance 13.70 Pain Relevance 0.67

endosome (CDK2) nucleoplasm (CDK2) cytoplasm (CDK2) cytosol (CDK2) mitosis (CDK2) nucleus (CDK2)

Anatomy Link Frequency HT-29 2 liver 1 telomere 1 RT4 1 CDK2 (Homo sapiens)

Pain Link Frequency Relevance Heat withdrawal 52 98.72 Inflammation 75 98.16 palliative 3 79.52 metalloproteinase 27 72.08 cINOD 4 66.08 Inflammatory response 13 65.04 Spinal cord 48 57.00 qutenza 9 50.00 antagonist 29 46.00 Opioid 68 5.00

Disease Link Frequency Relevance Heat Retinoblastoma 136 100.00 Melanoma 73 100.00 Bullous Skin Disease 304 99.80 Acantholysis 65 99.12 Apoptosis 387 98.60 INFLAMMATION 92 98.16 Hepatocellular Cancer 132 97.76 Hypoxia 144 96.68 Cancer 598 94.60 Death 104 89.68

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The expression of Cdk2 protein did not change following OGF exposure (Fig. 2C).

Gene_expression (expression) of Cdk2

1) Confidence 0.63 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2253554 Disease Relevance 0.64 Pain Relevance 0

The pre-treatment of cells with CQ inhibited the down-regulation of p21Cip1 and p27Kip1 expressions induced by 5-FU and, on the other hand, inhibited the up-regulation of the expression of CDK2.

Gene_expression (expression) of CDK2

2) Confidence 0.58 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2914703 Disease Relevance 0 Pain Relevance 0

Treatment of HT-29 cells with 5-FU resulted in decreased expressions of p21Cip1 and p27Kip1, and simultaneously in increased expression of CDK2.

Gene_expression (expression) of CDK2 in HT-29

3) Confidence 0.58 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2914703 Disease Relevance 0 Pain Relevance 0

To verify whether the OGF-induced downregulation of pRb was associated with changes in Cdk2, Cdk2 expression and activity levels were determined.

Spec (determined) Gene_expression (expression) of Cdk2

4) Confidence 0.54 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2253554 Disease Relevance 0.66 Pain Relevance 0

p21/Cdk2 assay

Gene_expression (assay) of Cdk2

5) Confidence 0.54 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2253554 Disease Relevance 0 Pain Relevance 0

Pre-treatment of cells with CQ inhibited the down-regulation of p21Cip1 and p27Kip1 expression induced by 5-FU and, on the other hand, decreased the expression of CDK2 (Fig. 7).

Gene_expression (expression) of CDK2

6) Confidence 0.45 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2914703 Disease Relevance 0.21 Pain Relevance 0

Treatment of HT-29 cells with 5-FU alone resulted in decreased expression of p21Cip1 and p27Kip1, and simultaneously in increased expression of CDK2, as detected by Western blot.

Gene_expression (expression) of CDK2 in HT-29

7) Confidence 0.45 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2914703 Disease Relevance 0.12 Pain Relevance 0

Treatment with lovastatin or celecoxib decreased the levels of cyclin D1, CDK2, pRb and E2F1, while the combination treatment showed more pronounced suppression.

Gene_expression (levels) of CDK2

8) Confidence 0.45 Published 2009 Journal Int. J. Oncol. Section Abstract Doc Link 19787257 Disease Relevance 0.33 Pain Relevance 0.07

The genes that encode Cyclin E and CDK2 were both placed in the core group.

Gene_expression (encode) of CDK2

9) Confidence 0.42 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2791157 Disease Relevance 0.21 Pain Relevance 0

DCT, CDK2, BCL2, GPR143) despite having relatively higher MITF expression (Figure 1B, C), indicating that there are probably melanoma sub-types present within the broad Motif 1 and 2 classifications, and that not all cell lines with lower MITF have a Motif 1 expression profile.

Gene_expression (expression) of CDK2 associated with melanoma

10) Confidence 0.40 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2794539 Disease Relevance 0.32 Pain Relevance 0

CDK2 expression increased in HR (49%, P < 0.05) respect to control and HC groups, while no variation was detected in CDK4 in any of the tested groups (Fig. 2).

Gene_expression (expression) of CDK2 associated with hepatocellular cancer

11) Confidence 0.31 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1769509 Disease Relevance 0.28 Pain Relevance 0.04

Furthermore, we showed the abnormal expression of cyclin E and CDK2 in HR group which could be associated to the inflammatory process [16].

Gene_expression (expression) of CDK2 associated with inflammation

12) Confidence 0.31 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1769509 Disease Relevance 0.95 Pain Relevance 0.09

Hence, we analyzed the hepatic expression of cyclin E, CDK2, CDK4 and the cell cycle inhibitor p21cip1/waf1 in animals receiving continuous dietary DAB (HC) and in the HR animals.

Spec (analyzed) Gene_expression (expression) of CDK2 associated with hepatocellular cancer

13) Confidence 0.31 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1769509 Disease Relevance 0.24 Pain Relevance 0.05

Expression of AR-regulated cell cycle genes, such as A-, B- and D-type cyclins, cyclin-dependent kinases (CDK1, CDK2, CDK4, CDK6) and cyclin-dependent kinase inhibitors (CDKN1B, CDKN2A, CDKN2B), was generally unaffected [40], [41], [42], [43], [44], [45].

Gene_expression (Expression) of CDK2

14) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2957443 Disease Relevance 0 Pain Relevance 0

Similar results showing that SHP1 downregulation effected p27Kip1 expression and Cdk2-cyclin E complex formation have been reported [43].

Gene_expression (expression) of Cdk2

15) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2908539 Disease Relevance 0.07 Pain Relevance 0

Cyclin E and CDK2 protein levels are increased after carcinogen withdrawal

Gene_expression (levels) of CDK2 associated with withdrawal

16) Confidence 0.26 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1769509 Disease Relevance 0.14 Pain Relevance 0.05

Left branch shows distinctive underexpression and loss of expression areas with genes such as IFNGR2, interleukin 2, laminin B1, MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR and PGS2, among others, and a few overexpressed genes such as MIF, CDK 2, 5, and 7, RPSA, JUP and ITGAE.

Gene_expression (underexpression) of CDK 2

17) Confidence 0.26 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1198222 Disease Relevance 0.63 Pain Relevance 0.04

Left branch shows distinctive underexpression and loss of expression areas with genes such as IFNGR2, interleukin 2, laminin B1, MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR and PGS2, among others, and a few overexpressed genes such as MIF, CDK 2, 5, and 7, RPSA, JUP and ITGAE.

Gene_expression (overexpressed) of CDK 2

18) Confidence 0.26 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1198222 Disease Relevance 0.58 Pain Relevance 0.04

Left branch shows distinctive underexpression and loss of expression areas with genes such as IFNGR2, interleukin 2, laminin B1, MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR and PGS2, among others, and a few overexpressed genes such as MIF, CDK 2, 5, and 7, RPSA, JUP and ITGAE.

Gene_expression (expression) of CDK 2

19) Confidence 0.26 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1198222 Disease Relevance 0.62 Pain Relevance 0.04

Our treatment also reduced the expression of cyclin D1, cyclin D2, p-Rb and cyclin E while the expression of Cdk2 was unaffected.

Gene_expression (expression) of Cdk2

20) Confidence 0.24 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2908539 Disease Relevance 0.25 Pain Relevance 0

General Comments

This test has worked.